Drug Trial Radar · NCT05352672
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,546
Actual
Start
Jul 14, 2022
Primary completion
Mar 12, 2026
Study completion Sep 16, 2031
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medication, pembrolizumab, approved for the treatment of melanoma skin cancer in adults, and to observe any similarities, or differences, in how the study drugs work in adolescent participants compared with adult participants. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life
Conditions
- Melanoma
Interventions
FianlimabDrug
Intravenous (IV) infusion
CemiplimabDrug
IV infusion
PembrolizumabDrug
IV infusion
PlaceboDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Approximately 27 months
Locations
210 sites in 24 countries. Site status is shown where the registry gives one.
UC San Diego
La Jolla, California
The Angeles Clinic and Research Institute
Los Angeles, California
Orlando Health
Orlando, Florida
Seidman Cancer Center
Cleveland, Ohio
University of Tennessee Medical Center
Knoxville, Tennessee
Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)
Buenos Aires, Argentina
Exelsus
San Miguel de Tucumán, Argentina
DIABAID - Instituto de Asistencia Integral en Diabetes
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Centro Medico Austral
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Centro de Investigacion Pergamino
Pergamino, Buenos Aires, Argentina
Instituto de Oncologia de Rosario
Rosario, Santa Fe Province, Argentina
Gold Coast Hospital and Health Service
Southport, Queensland, Australia
Townsville University Hospital
Townsville, Queensland, Australia
Calvary North Adelaide Hospital
North Adelaide, South Australia, Australia
Icon Cancer Centre Hobart
Hobart, Tasmania, Australia
Andrew Love Cancer Centre
Geelong, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Medical University Vienna
Vienna, Austria
University Hospital Saint Poelten
Sankt Pölten, Lower Austria, Austria
Medical University of Graz
Graz, Styria, Austria
Medical University Innsbruck
Innsbruck, Tyrol, Austria
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Centre Hospitalier Universitaire Universite Catholique de Louvain Namur Site Sainte Elisabeth
Namur, Belgium
AZ Groeninge
Kortrijk, West-Vlaanderen, Belgium
AZ Nikolaas
Sint-Niklaas, West-Vlaanderen, Belgium
Oncosite Centro De Pesquisa Em Oncologia
Ijuí, Brazil
INCA - Brazilian National Cancer Institute
Rio de Janeiro, Brazil
Instituto COI
Rio de Janeiro, Brazil
Hemomed
São Paulo, Brazil
Hospital Sirio Libanes
São Paulo, Brazil
Sao Camilo Oncologia
São Paulo, Brazil
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil
Hospital das Clinicas da Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil
Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
Hospital Bruno Born
Lajeado, Rio Grande do Sul, Brazil
Instituto do Cancer em Hospital Sao Vicente de Paulo
Passo Fundo, Rio Grande do Sul, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Moinhos de vento
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisa em Oncologia PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Fundacao Pio XII - Hospital de Amor Amazonia
Porto Velho, Rondônia, Brazil
Showing 40 of 210 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.